| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.2 |
| mRNA | AMG-706 | FIMM | pan-cancer | AAC | 0.22 | 0.2 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.2 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.21 | 0.2 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |